Migsun (Naproxen Sodium, Sumatriptan Succinate)

Naproxen sodium reduces inflammation by inhibiting cyclooxygenase enzymes, decreasing prostaglandin production. Sumatriptan succinate activates 5‑HT1B/1D receptors, causing cranial blood‑vessel constriction and blocking pain signals from the trigeminal nerve, together delivering fast migraine relief.

The specific dose and dosing schedule of Migsun are determined by the prescribing healthcare professional based on individual patient needs, severity of migraine, and clinical guidelines. Patients should follow the prescriber’s instructions exactly.

Safety of Migsun in pregnancy or while breastfeeding has not been fully established. Healthcare providers should weigh potential benefits against risks and consider alternative therapies when treating pregnant or nursing patients.

To order Migsun, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Migsun combines an NSAID with a triptan, offering both anti‑inflammatory and vasoconstrictive actions in a single tablet. Compared with single‑agent triptans, it may provide faster pain relief and reduce the need for additional NSAID use, while still sharing similar safety considerations.

Migsun should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use after the expiration date.

Migsun is taken orally, usually as a whole tablet, with or without water. It should be taken as soon as migraine symptoms begin, unless otherwise directed by a healthcare professional.

Serious risks include cardiovascular events such as chest pain or heart attack, severe allergic reactions (anaphylaxis), serotonin syndrome when combined with other serotonergic drugs, and significant hypertension. Patients should seek immediate medical attention if these symptoms occur.

Migsun is contraindicated in patients with known hypersensitivity to naproxen, sumatriptan, or any component of the formulation, as well as those with uncontrolled hypertension, recent cardiovascular events, severe hepatic or renal impairment, and individuals taking MAO inhibitors or other triptans.